1. Home
  2. HYPR vs CELU Comparison

HYPR vs CELU Comparison

Compare HYPR & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hyperfine Inc.

HYPR

Hyperfine Inc.

N/A

Current Price

$1.16

Market Cap

107.9M

Sector

Health Care

ML Signal

N/A

Logo Celularity Inc.

CELU

Celularity Inc.

N/A

Current Price

$1.22

Market Cap

34.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
HYPR
CELU
Founded
2014
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Medical Specialities
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
107.9M
34.5M
IPO Year
2021
N/A

Fundamental Metrics

Financial Performance
Metric
HYPR
CELU
Price
$1.16
$1.22
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
1
Target Price
$1.28
$6.00
AVG Volume (30 Days)
283.6K
28.0K
Earning Date
04-20-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
9.68
N/A
EPS
N/A
N/A
Revenue
$12,890,000.00
N/A
Revenue This Year
$5.96
N/A
Revenue Next Year
$34.43
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
16.84
N/A
52 Week Low
$0.53
$1.01
52 Week High
$2.22
$4.35

Technical Indicators

Market Signals
Indicator
HYPR
CELU
Relative Strength Index (RSI) 55.82 50.50
Support Level $1.04 $1.21
Resistance Level $1.19 $1.33
Average True Range (ATR) 0.07 0.11
MACD 0.00 0.00
Stochastic Oscillator 70.73 48.10

Price Performance

Historical Comparison
HYPR
CELU

About HYPR Hyperfine Inc.

Hyperfine Inc is a medical device company that created Swoop. The Swoop Portable MR Imaging System produces high-quality images at a lower magnetic field strength than conventional MRI scanners. The company derives its revenue from sale of sales of MRI devices and service sales which consist of sales from subscriptions of bundled devices, maintenance, and software.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: